Multiple Advantages Before and After Radical Prostatectomy with Combined Endocrine Therapy

  • G. Monfette
  • A. Dupont
  • F. Labrie
  • J. Gagnon
  • S. Pinault
  • J.-C. Boivin
  • B. Tetu


Cancer of the prostate has become, with lung cancer, the most common cancer in men. It is estimated that 98000 new cases of prostate cancer would be diagnosed in the United States in 1988 [1]. In addition, cancer of the prostate is the second leading cause of cancer death in men. Prostatic carcinoma is found in 6%–10% of prostatectomy specimens after resection for benign prostatic hyperplasia by routine sectioning. However, the incidence rate increases to 25%–40% if step sections are used [2, 3]. At autopsy, a similar incidence is found, namely 15%–17% by random sections and 46%–57% by step sections [4]. The lifetime probability of diagnosis of this disease is 5.2% and 9.6% in White and Black men, respectively [5]. In addition to the high frequency of this disease, diagnosed in one out of 20 men during their lifetime, more than 50% of the patients have reached the stage of metastases (D1 or D2) when the cancer is first discovered. At this late stage, endocrine therapy is the standard and only efficient treatment [6] (for review, see [7]).


Radical Prostatectomy Seminal Vesicle Transrectal Ultrasound Seminal Vesicle Invasion Multiple Advantage 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Cancer Statistics (1988) CA 37(1)Google Scholar
  2. 2.
    Denton SE, Choy SH, Valk WL (1965) J Urol 93:296PubMedGoogle Scholar
  3. 3.
    Joslin AH, Lich R Jr, Barnes ML (1961) South Med J 54:233PubMedCrossRefGoogle Scholar
  4. 4.
    Baron E, Angrist A (1941) Arch Pathol 32:898Google Scholar
  5. 5.
    Mettlin C, Natarajan N (1983) Prostate 4:323PubMedCrossRefGoogle Scholar
  6. 6.
    Jordan WP Jr, Blackard CE, Byar DP (1977) South Med J 70:1411PubMedGoogle Scholar
  7. 7.
    Labrie F, Dupont A, Bélanger A (1987) In: Ratliff TL, Catalona WJ (eds) Genitourinary cancer. Nijhoff, Boston, pp 157–200CrossRefGoogle Scholar
  8. 8.
    Dupont A, Labrie F, Giguère M, Borsanyi JP, Lacourcière Y, Bergeron N, Cusan L, Bélanger A, Emond J (1988) Eur J Cancer Clin Oncol 24:659PubMedCrossRefGoogle Scholar
  9. 9.
    Labrie F, Dupont A, Bélanger A, St-Arnaud R, Giguère M, Lacourcière Y, Emond J, Monfette G (1986) Endocrinol Rev 7:67CrossRefGoogle Scholar
  10. 10.
    Labrie F, Veilleux R (1986) Prostate 8:293PubMedCrossRefGoogle Scholar
  11. 11.
    Luthy I, Labrie F (1987) Prostate 10:89PubMedCrossRefGoogle Scholar
  12. 12.
    Labrie F, Veilleux R, Fournier A (1988) J Natl Cancer Inst 80:967Google Scholar
  13. 13.
    Walsh PC, Lepor H, Eggleston JC (1983) Prostate 4:473PubMedCrossRefGoogle Scholar
  14. 14.
    Brochu M, Bélanger A (1987) J Clin Endocrinol Metab 64:1283PubMedCrossRefGoogle Scholar
  15. 15.
    Rodbard D, Lewald JE (1970) In: Diczfalusy E (ed) Second Karoliska symposium on research methods in reproductive endocrinology. Geneva, pp 79–103Google Scholar
  16. 16.
    Kramer CY (1956) Biometrics 12:307CrossRefGoogle Scholar
  17. 17.
    Tremblay A, Bélanger A (1984) Contraception 4:483CrossRefGoogle Scholar
  18. 18.
    Lacoste D (1988) 70th Ann Endocrine Society abst # 1210Google Scholar
  19. 19.
    Paulson D, Hodge GB Jr, Hinshaw W, The Uro-Oncology Research Group (1984) J Urol 131:901PubMedGoogle Scholar
  20. 20.
    Anonymous (1987) Prostate cancer consensus hampered by lack of data. Science 236:1627 (editorial)Google Scholar
  21. 21.
    Stamey TA, McNeal JE, Freiha FS, Redwine E (1988) J Urol 139:1235PubMedGoogle Scholar
  22. 22.
    Juban DA, El-Mahdi AM, Schellhammer PF (1987) Urology 30:420CrossRefGoogle Scholar
  23. 23.
    Cupps RE, Utz DC, Fleming TR, Carson CC, Zinckle H, Myers RP (1980) J Urol 124:855PubMedGoogle Scholar
  24. 24.
    Grayhack JT, Assimos DG (1983) Prostate 4:13PubMedCrossRefGoogle Scholar
  25. 25.
    Barzell W, Bean MA, Hilaris BS, Whitmore WF (1977) J Urol 118:278PubMedGoogle Scholar
  26. 26.
    Gleason DF, Mellinger GT (1974) J Urol 111:58PubMedGoogle Scholar
  27. 27.
    Roberts S, Jonasson O, Long L, McGrew EA, McGrath R, Cole WH (1962) Cancer 15:232PubMedCrossRefGoogle Scholar
  28. 28.
    Forman JD, Order E, Zinreich ES, Lee DJ, Wharam MD, Mellits ED (1986) Cancer 58:1770PubMedCrossRefGoogle Scholar
  29. 29.
    Fleischman JD, Catalona WJ (1985) J Urol 134:498Google Scholar
  30. 30.
    Jonasson O, Long L, Roberts S, McGraw E, McDonald JH (1961) J Urol 85:1Google Scholar
  31. 31.
    Hanks GE, Leibel S, Kramer S (1983) J Urol 129:309PubMedGoogle Scholar
  32. 32.
    McGowan DG (1980) Int J Radiol Oncol Biol Phys 6:1121CrossRefGoogle Scholar
  33. 33.
    Crevey, Webb (1947) Surgery 21:56Google Scholar
  34. 34.
    Veterans Administration Cooperative Urological Group (VACURG) (1967) Gynecol Obstet 124:1011Google Scholar
  35. 35.
    Barnes RW, Ninan CA (1972) J Urol 108:897PubMedGoogle Scholar
  36. 36.
    Zinckle H (1987) In: Management of clinical localized prostate cancer, NIH Consensus Conference, pp 77–80Google Scholar
  37. 37.
    Zincke H, Utz DC (1983) Semin Urol 1:253PubMedGoogle Scholar
  38. 38.
    Zincke H, Utz DC, Taylor WF (1986) J Urol 135:1199PubMedGoogle Scholar
  39. 39.
    Zincke H, Utz DC, Thulé PM, Taylor WF (1987) Urology 30:307PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1991

Authors and Affiliations

  • G. Monfette
  • A. Dupont
  • F. Labrie
  • J. Gagnon
  • S. Pinault
  • J.-C. Boivin
  • B. Tetu
    • 1
    • 2
    • 3
    • 4
    • 5
  1. 1.Hôtel-Dieu St. JérômeQuébecCanada
  2. 2.Endocrinology molecularLaval University Medical CenterQuebecCanada
  3. 3.Radiology DepartmentLaval University Medical CenterQuebecCanada
  4. 4.Pathology departmentHôtel-Dieu St-JérômeQuebecCanada
  5. 5.Pathology departmentHôtel-Dieu QuebecQuebecCanada

Personalised recommendations